The stock of Relay Therapeutics Inc (RLAY) has seen a -10.16% decrease in the past week, with a 16.94% gain in the past month, and a -24.33% decrease in the past quarter. The volatility ratio for the week is 11.70%, and the volatility levels for the past 30 days are at 9.83% for RLAY. The simple moving average for the past 20 days is -6.95% for RLAY’s stock, with a -43.60% simple moving average for the past 200 days.
Is It Worth Investing in Relay Therapeutics Inc (NASDAQ: RLAY) Right Now?
The 36-month beta value for RLAY is at 1.62. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 5 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for RLAY is 129.29M, and currently, shorts hold a 15.06% of that float. The average trading volume for RLAY on May 14, 2025 was 2.64M shares.
RLAY) stock’s latest price update
Relay Therapeutics Inc (NASDAQ: RLAY) has experienced a decline in its stock price by -9.00 compared to its previous closing price of 3.11. However, the company has seen a fall of -10.16% in its stock price over the last five trading days. globenewswire.com reported 2025-05-08 that CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats:
Analysts’ Opinion of RLAY
Many brokerage firms have already submitted their reports for RLAY stocks, with Wells Fargo repeating the rating for RLAY by listing it as a “Equal Weight.” The predicted price for RLAY in the upcoming period, according to Wells Fargo is $4 based on the research report published on April 17, 2025 of the current year 2025.
Jefferies, on the other hand, stated in their research note that they expect to see RLAY reach a price target of $16, previously predicting the price at $10.60. The rating they have provided for RLAY stocks is “Buy” according to the report published on September 10th, 2024.
Goldman gave a rating of “Buy” to RLAY, setting the target price at $20 in the report published on September 10th of the previous year.
RLAY Trading at -4.60% from the 50-Day Moving Average
After a stumble in the market that brought RLAY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.60% of loss for the given period.
Volatility was left at 9.83%, however, over the last 30 days, the volatility rate increased by 11.70%, as shares surge +10.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.56% lower at present.
During the last 5 trading sessions, RLAY fell by -10.16%, which changed the moving average for the period of 200-days by -68.76% in comparison to the 20-day moving average, which settled at $3.04. In addition, Relay Therapeutics Inc saw -31.31% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RLAY starting from Rahmer Peter, who sale 10,739 shares at the price of $3.00 back on Apr 30 ’25. After this action, Rahmer Peter now owns 390,081 shares of Relay Therapeutics Inc, valued at $32,217 using the latest closing price.
Rahmer Peter, the of Relay Therapeutics Inc, sale 1,364 shares at $3.17 during a trade that took place back on Apr 28 ’25, which means that Rahmer Peter is holding 400,820 shares at $4,324 based on the most recent closing price.
Stock Fundamentals for RLAY
Current profitability levels for the company are sitting at:
- -49.27 for the present operating margin
- -0.12 for the gross margin
The net margin for Relay Therapeutics Inc stands at -43.42. The total capital return value is set at -0.5. Equity return is now at value -45.46, with -40.64 for asset returns.
Based on Relay Therapeutics Inc (RLAY), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -5.77.
Currently, EBITDA for the company is -372.47 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of 57.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.96.
Conclusion
In conclusion, Relay Therapeutics Inc (RLAY) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
